All In Biotech

NDA 022363 · Kowa CO

Livalo

Pitavastatin Calcium · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Mar 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Aug 3, 2009

Approved uses

3

Original approval plus efficacy supplements

Registered trials

112

25 Phase 3, 12 recruiting

FAERS reports

8,612

6,027 serious, 706 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 31, 2026.

LIVALO is indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). LIVALO is a HMG-CoA reductase inhibitor (statin) indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: ( 1 ) Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).

Mechanism: Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very low density lipoproteins.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • LIVALO · PITAVASTATIN CALCIUM EQ 2MG BASE · TABLET, ORAL · Prescription · TE AB
  • LIVALO · PITAVASTATIN CALCIUM EQ 4MG BASE · TABLET, ORAL · Prescription · TE AB
  • LIVALO · PITAVASTATIN CALCIUM EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Pitavastatin" as an intervention, any sponsor and status, largest first.

All 112 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myalgia480
  • diarrhoea393
  • nausea374
  • fatigue359
  • anaemia300
  • headache298
  • dizziness297
  • arthralgia295
  • rash287
  • off label use265
  • dyspnoea260
  • drug ineffective254

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20059
200625
200738
200867
200978
2010171
2011274
2012545
2013375
2014553
2015660
2016725
2017707
2018685
2019656
2020515
2021417
2022477
2023419
2024526
2025383
2026303

Recalls

2 FDA enforcement reports for this application.

  • Feb 24, 2025 · Class III · Completed

    Presence of foreign tablets/capsules

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Livalo (Pitavastatin Calcium)

2024 spending

$90.6M

Beneficiaries

37,775

143,372 claims

Per beneficiary

$2,399

$10.41 per unit

View as table
YearSpending
2020$189,564,416
2021$206,236,202
2022$206,857,254
2023$189,914,605
2024$90,623,325

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 274 on PubMed

Sponsor: Kowa CO

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.